Used in the treatment of certain cancers, particularly those involving abnormal FGFR pathway signaling due to fusions or mutations in Fibroblast Growth Factor Receptor (FGFR) proteins. It works by selectively inhibiting FGFR1, FGFR2, and FGFR3 kinases, which contribute to cancer cell growth, survival, and proliferation. This compound, known as pemigatinib, is approved for use in FGFR2 fusion-positive cholangiocarcinoma and is being studied in clinical trials for its potential efficacy in other FGFR-altered solid tumors and hematologic malignancies. Researchers are exploring its use as a targeted therapy to minimize side effects compared to traditional chemotherapy.